Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | PRKACG | P22612 | 1/20 | 0.31 |
| ▸ | PRKACB | P22694 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418645 | 0.67 | — | — | |
| SCHEMBL2044081 | 0.62 | — | — | |
| SCHEMBL9590177 | 0.62 | — | — | |
| SCHEMBL13122485 | 0.57 | GSK3A (0.33) | — | |
| SCHEMBL9901679 | 0.56 | — | — | |
| SCHEMBL9902594 | 0.55 | — | — | |
| SCHEMBL49151 | 0.53 | — | — | |
| SCHEMBL13407 | 0.53 | — | — | |
| SCHEMBL10874064 | 0.53 | — | — | |
| SCHEMBL2040553 | 0.51 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079886-B2 | Substituted triazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-07-14 | — | — | US | claimed |
| EP-2523949-B1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | claimed |
| US-20120295891-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | claimed |
| US-5157037-A | α-arylacrylates substituted by a heterocyclic radical, and fungicides which contain these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1992-10-20 | — | — | US | claimed |
| US-9079886-B2 | Substituted triazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| EP-2523949-B1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20120295891-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
| US-5378711-A | α-arylacrylates substituted by a heterocyclic radical, and fungicides which contain these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1995-01-03 | — | — | US | disclosed |
| US-5326767-A | α-arylacrylates substituted by a heterocyclic radical, and fungicides which contain these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1994-07-05 | — | — | US | disclosed |
| US-5194438-A | Plant safe fungicides | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-16 | — | — | US | disclosed |
| US-5157037-A | α-arylacrylates substituted by a heterocyclic radical, and fungicides which contain these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1992-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | PRKACA 85/4885PRKACG 104/4885PRKACB 135/4885 |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | PRKACA 35/4885PRKACG 63/4885PRKACB 61/4885 |
| US-20120295891-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | PRKACA 2595/4885PRKACG 3018/4885PRKACB 2779/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | PRKACA 24/4885PRKACG 42/4885PRKACB 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.